Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Cantor Fitzgerald
AstraZeneca
Harvard Business School
Cerilliant
Cipla
Farmers Insurance
Daiichi Sankyo
Accenture

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,092,832

« Back to Dashboard

Which drugs does patent 8,092,832 protect, and when does it expire?

Patent 8,092,832 protects FENTORA and is included in one NDA.

This patent has fifty-eight patent family members in twenty-seven countries.
Summary for Patent: 8,092,832
Title:Generally linear effervescent oral fentanyl dosage form and methods of administering
Abstract: Fentanyl containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than know oral formulation and have advantages in terms of cost and side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.
Inventor(s): Moe; Derek (Maple Grove, MN), Agarwal; Vikas (Plymouth, MN), Habib; Walib (Crystal, MN)
Assignee: Cephalon, Inc. (Frazer, PA)
Application Number:12/955,229
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,092,832
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Delivery;

Drugs Protected by US Patent 8,092,832

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-001 Sep 25, 2006 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-002 Sep 25, 2006 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-003 Sep 25, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-004 Sep 25, 2006 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,092,832

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,862,833 Effervescent oral opiate dosage forms and methods of administering opiates ➤ Sign Up
7,858,121 Effervescent oral fentanyl dosage form and methods of administering fentanyl ➤ Sign Up
8,298,577 Effervescent oral opiate dosage forms and methods of administering opiates ➤ Sign Up
8,119,158 Effervescent oral fentanyl dosage form and methods of administering fentanyl ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Healthtrust
Daiichi Sankyo
US Department of Justice
Dow
Chubb
QuintilesIMS
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.